In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...

Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Biogen remains focused on advancing its immunology and rare disease pipeline, including three Phase 3 trials for Felzartamab in 2025. Q4 non-GAAP diluted EPS was $3.44 compared to analysts ...

Biogen Inc. (NASDAQ ... which includes Phase 3 trials for Felzartamab, a treatment for multiple myeloma and kidney diseases. Viehbacher commented, “So, you know, the race really that we are ...

Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...

Biogen's development organization had another ... is only the third agent with a positive global Phase III study in SLE. Additionally, Felzartamab was granted orphan drug designation in the ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Thanks, Jennifer, and good morning, and welcome to Biogen's fourth-quarter and full ... but I think we feel particularly excited about felzartamab and the potential this could have in rare kidney ...